TrialDiabetes, obesity & metabolism2025

iGlarLixi provides improved early glycaemic control after 12 weeks of treatment compared with basal insulin in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN studies.

Lulu Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.